Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial
Saved in:
| Title: | Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial |
|---|---|
| Authors: | Hubalewska-Dydejczyk, Alicja1 (AUTHOR), Decristoforo, Clemens2 (AUTHOR), Mikolajczak, Renata3 (AUTHOR), Kolenc, Petra4,5 (AUTHOR), Opalinska, Marta1 (AUTHOR), Garnuszek, Piotr3 (AUTHOR), Skorkiewicz, Konrad6 (AUTHOR), Glowa, Bogusław7 (AUTHOR), Trofimiuk-Muldner, Malgorzata1 (AUTHOR), Studen, Andrej8 (AUTHOR), Simoncic, Urban8 (AUTHOR), Rangger, Christine2 (AUTHOR), di Santo, Gianpaolo2 (AUTHOR), Fani, Melpomeni9 (AUTHOR), Virgolini, Irene2 (AUTHOR), Lezaic, Luka4,10 (AUTHOR) luka.lezaic@kclj.si |
| Source: | Journal of Nuclear Medicine. Jun2026, Vol. 67 Issue 6, p895-902. 8p. |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 01615505 |
|---|---|
| DOI: | 10.2967/jnumed.125.270347 |
